Uther faces an alleged-scam accusation at the top of five distinct concern themes — alongside endotoxin questions, credibility doubts over lab reports, stock shortfalls, and pricing complaints — that together generated 81 community mentions this window.

If kept as a standalone breaking alert, lead with the substance: 'Researchers are publicly reconsidering large retatrutide reserves in a fast-moving 36-post thread, with degradation timelines and pipeline uncertainty cited as the primary brakes on stockpiling behavior.'

A 36-post thread on research-community forums surfaces a measurable shift in how researchers are sizing their retatrutide reserves, with participants questioning whether large inventory positions will survive the pace of pipeline development. a community member named degradation data as the limiting factor: 'the early long-term degradation data on reta is what keeps me from getting too carried away on the stash.' a community member disclosed holding roughly four years each of tirzepatide and retatrutide — 'FOMO as I haven't even tried it yet' — while still scanning vendor posts daily, signaling that accumulation instinct persists even as the thread's dominant tone runs skeptical.

The thread appeared in a window that logged 571 total posts across 171 threads from 277 authors, down from 338 authors in the prior period. That contraction in participation is the available context; whether the stockpile-skepticism tone in this thread is representative of the broader window cannot be established from thread count alone.